پديد آورندگان :
Nikeghbalian Saman نويسنده , Malek-Hosseini Seyyed-Ali نويسنده , Salahi Heshmatollah نويسنده , Bahador Ali نويسنده , Geramizadeh Bita نويسنده , Salehipour Mehdi نويسنده , Davari Hamid-Reza نويسنده , Kazemi Kourosh نويسنده , Nejatollahi Seyed-Mohammad-Reza نويسنده , Dehghani Masood نويسنده , Kakaei Farzad نويسنده , Ghaffaripour Sina نويسنده , Roozbeh Jamshid نويسنده , Sagheb Mohammad-Mehdi نويسنده , Rais-Jalali Ghanbar-Ali نويسنده , Gholami Siavash نويسنده
چكيده لاتين :
Background: Pancreas transplantation is the treatment of choice for selected patients with
type 1 diabetes mellitus. We reviewed our first 40 patients who underwent pancreas transplantation
in Shiraz Organ Transplant Center.
Methods: Between April 2006 and April 2008, we performed pancreas transplantation on 40
recipients. The operation included portal venous drainage and exocrine enteric drainage.
Immunosuppressive therapy included prednisolone, tacrolimus, and mycophenolate mofetil.
Ganciclovir was administered as prophylaxis for cytomegalovirus. Peri-operative and regular
follow up data on survival and complication were gathered and analyzed.
Results: The mean follow-up was 10.1±6.5 months (range: 1 – 24 months). Mean age of donors
and recipients was 23.6±8.2 and 32.30±8.9 years, respectively. The mean pretransplant insulin
consumption was 43.75±17.4 IU. Fasting blood glucose before transplantation was 275.5±72.3
mg/dL that decreased to 95.6±7.01 at six months follow-up (P<0.001). Complications were as
follows: re-exploration (n=9), gastrointestinal complications (n=10), acute rejection episodes
(n=12), and chronic rejection (n=4). We lost one patient due to diffuse cytomegalovirus and
aspergillus infection three months after the operation with a functioning graft. Overall graft survival
was 84.9% and patient survival 97.5%.
Conclusion: Good patient and graft survival in these series encouraged us to continue the
program with all its difficulties.
